These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 37895314)

  • 1. Lung Inflammatory Genes in Cystic Fibrosis and Their Relevance to Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapies.
    Carbone A; Vitullo P; Di Gioia S; Conese M
    Genes (Basel); 2023 Oct; 14(10):. PubMed ID: 37895314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifier Factors of Cystic Fibrosis Phenotypes: A Focus on Modifier Genes.
    Mésinèle J; Ruffin M; Guillot L; Corvol H
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation.
    Caverly LJ; Riquelme SA; Hisert KB
    Clin Chest Med; 2022 Dec; 43(4):647-665. PubMed ID: 36344072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine.
    Sepahzad A; Morris-Rosendahl DJ; Davies JC
    Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33924524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
    Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
    J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.
    Wang S; Niroula S; Hoffman A; Khorrami M; Khorrami M; Yuan F; Gasser GN; Choi S; Liu B; Li J; Metersky ML; Vincent M; Crum CP; Boucher RC; Karmouty-Quintana H; Huang HJ; Sheshadri A; Dickey BF; Parekh KR; Engelhardt JF; McKeon FD; Xian W
    Am J Respir Crit Care Med; 2023 Nov; 208(9):930-943. PubMed ID: 37695863
    [No Abstract]   [Full Text] [Related]  

  • 7. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.
    Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C
    Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators.
    Colombo C; Ramm GA; Lindblad A; Corti F; Porcaro L; Alghisi F; Asherova I; Evans H; Kashirskaya N; Kondratyeva E; Lewindon PJ; de Monestrol I; Oliver M; Ooi CY; Padoan R; Shankar S; Alicandro G
    J Cyst Fibros; 2023 Mar; 22(2):263-265. PubMed ID: 36739240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic fibrosis transmembrane conductance regulator dysfunction in platelets drives lung hyperinflammation.
    Ortiz-Muñoz G; Yu MA; Lefrançais E; Mallavia B; Valet C; Tian JJ; Ranucci S; Wang KM; Liu Z; Kwaan N; Dawson D; Kleinhenz ME; Khasawneh FT; Haggie PM; Verkman AS; Looney MR
    J Clin Invest; 2020 Apr; 130(4):2041-2053. PubMed ID: 31961827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting airway inflammation in cystic fibrosis.
    McElvaney OJ; Wade P; Murphy M; Reeves EP; McElvaney NG
    Expert Rev Respir Med; 2019 Nov; 13(11):1041-1055. PubMed ID: 31530195
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.
    Kramer-Golinkoff E; Camacho A; Kramer L; Taylor-Cousar JL
    Pediatr Pulmonol; 2022 May; 57(5):1253-1261. PubMed ID: 35170259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
    Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
    Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Cystic Fibrosis Lung Disease and Lung Transplantation in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators.
    O'Carroll M
    Semin Respir Crit Care Med; 2023 Apr; 44(2):260-268. PubMed ID: 36893762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy.
    McDonald CM; Reid EK; Pohl JF; Yuzyuk TK; Padula LM; Vavrina K; Altman K
    Nutr Clin Pract; 2024 Apr; 39 Suppl 1():S57-S77. PubMed ID: 38429959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current evidence on the effect of highly effective CFTR modulation on interleukin-8 in cystic fibrosis.
    Williamson M; Casey M; Gabillard-Lefort C; Alharbi A; Teo YQJ; McElvaney NG; Reeves EP
    Expert Rev Respir Med; 2022 Jan; 16(1):43-56. PubMed ID: 34726115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Airway Inflammation and Host Responses in the Era of CFTR Modulators.
    Keown K; Brown R; Doherty DF; Houston C; McKelvey MC; Creane S; Linden D; McAuley DF; Kidney JC; Weldon S; Downey DG; Taggart CC
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32887484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CFTR Modulators: Current Status and Evolving Knowledge.
    Regard L; Martin C; Da Silva J; Burgel PR
    Semin Respir Crit Care Med; 2023 Apr; 44(2):186-195. PubMed ID: 36535667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of CFTR modulator therapies on CF airway microbiology.
    Rogers GB; Taylor SL; Hoffman LR; Burr LD
    J Cyst Fibros; 2020 May; 19(3):359-364. PubMed ID: 31416774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.